L Mind Study News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from L Mind Study. Real-time updates on events, politics, business and more.

Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting

July 31, 2023

Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.

Translating Recent Evidence Real World Management Refractory Diffuse Largeb Cell Lymphoma Largeb Cell Lymphoma Moving Novel Therapy Diffuse Largeb Cell Lymphoma

Source: onclive.com

Five-year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory DLBCL: Final Results From the Phase II L-MIND Study

May 25, 2023

Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Grzegorz Nowakowski Five Year Efficacy Patients With Relapsed Final Results From Partnership With Diffuse Largeb Cell Lymphoma

Source: onclive.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

L Mind Study News Today

Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting

Five-year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory DLBCL: Final Results From the Phase II L-MIND Study

Explore More Categories